Evidence map›Paper›PMID 29025325›Full record

ArticleInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2018

Versatility of targeted antibiotic-loaded gold nanoconstructs for the treatment of biofilm-associated bacterial infections.

Daniel G Meeker, Tengjiao Wang, Walter N Harrington, Vladimir P Zharov, Sarah A Johnson, Samir V Jenkins, Stephanie E Oyibo, Christopher M Walker, Weston B Mills, Mark E Shirtliff and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Fighting Methicillin-ResistantInternational journal of molecular sciences · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Nanobiosystems for Antimicrobial Drug-Resistant Infections.Nanomaterials (Basel, Switzerland) · 2021
    Review
  12. Review
  13. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  14. Article
  15. Article
  16. Review
  17. Antibody-Functionalized MoSFrontiers in bioengineering and biotechnology · 2019
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Daniel G Meekera Department of Microbiology and Immunology , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Tengjiao Wangb Department of Chemistry and Biochemistry , University of Arkansas , Fayetteville , AR , USA.
Walter N Harringtonc Phillips Classic Laser and Nanomedicine Laboratories , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Vladimir P Zharovc Phillips Classic Laser and Nanomedicine Laboratories , University of Arkansas for Medical Sciences , Little Rock , AR , USA.ORCID 0000-0003-4773-0548
Sarah A Johnsona Department of Microbiology and Immunology , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Samir V Jenkinsd Department of Radiation Oncology , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Stephanie E Oyibob Department of Chemistry and Biochemistry , University of Arkansas , Fayetteville , AR , USA.
Christopher M Walkera Department of Microbiology and Immunology , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Weston B Millsa Department of Microbiology and Immunology , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Mark E Shirtliffe Department of Microbial Pathogenesis , Dental School, University of Maryland-Baltimore , Baltimore , MD , USA.
Karen E Beenkena Department of Microbiology and Immunology , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Jingyi Chenb Department of Chemistry and Biochemistry , University of Arkansas , Fayetteville , AR , USA.
Mark S Smeltzera Department of Microbiology and Immunology , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
University of Arkansas for Medical Sciences · USUniversity of Arkansas at Fayetteville · USUniversity of Maryland, Baltimore · US

Funding

Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5M
Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
Pilot Grant ProgramP30GM145393 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Jason S Stumhofer · 2022 to 2026
$7.6M
Center for Protein Structure and FunctionP30GM103450 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI MILLETT, FRANCIS S · 2012 to 2014
$3.2M
Systems Pharmacology and Toxicology Training ProgramT32GM106999 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI PRATHER, PAUL L · 2013 to 2022
$1.4M
A nanotherapeutic approach to combat staphylococcal biofilm-associated infectionR56AI093126 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2011 to 2011
$360k
NCATS NIH HHS UL1 TR000039NIAID NIH HHS R56 AI093126NIGMS NIH HHS P20 GM103625NIGMS NIH HHS P30 GM103450NIGMS NIH HHS P30 GM145393NIGMS NIH HHS T32 GM106999
6 · The paper itself

Abstract

backgroundWe previously demonstrated that a photoactivatable therapeutic approach employing antibiotic-loaded, antibody-conjugated, polydopamine (PDA)-coated gold nanocages (AuNCs) could be used for the synergistic killing of bacterial cells within a biofilm. The approach was validated with a focus on Staphylococcus aureus using an antibody specific for staphylococcal protein A (Spa) and an antibiotic (daptomycin) active against Gram-positive cocci including methicillin-resistant S. aureus (MRSA). However, an important aspect of this approach is its potential therapeutic versatility.

methodsIn this report, we evaluated this versatility by examining the efficacy of AuNC formulations generated with alternative antibodies and antibiotics targeting S. aureus and alternative combinations targeting the Gram-negative pathogen Pseudomonas aeruginosa.

resultsThe results confirmed that daptomycin-loaded AuNCs conjugated to antibodies targeting two different S. aureus lipoproteins (SACOL0486 and SACOL0688) also effectively kill MRSA in the context of a biofilm. However, our results also demonstrate that antibiotic choice is critical. Specifically, ceftaroline and vancomycin-loaded AuNCs conjugated to anti-Spa antibodies were found to exhibit reduced efficacy relative to daptomycin-loaded AuNCs conjugated to the same antibody. In contrast, gentamicin-loaded AuNCs conjugated to an antibody targeting a conserved outer membrane protein were highly effective against P. aeruginosa biofilms.

conclusionsThese results confirm the therapeutic versatility of our approach. However, to the extent that its synergistic efficacy is dependent on the ability to achieve both a lethal photothermal effect and the thermally controlled release of a sufficient amount of antibiotic, they also demonstrate the importance of carefully designing appropriate antibody and antibiotic combinations to achieve the desired therapeutic synergy.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsBiofilmsGoldHumansNanoparticlesAnti-Bacterial AgentsGoldbiofilmsgold nanocagesPhotothermal killingPseudomonas aeruginosaStaphylococcus aureus

Identifiers

PMID29025325
PMCPMC6095133
OpenAlexW2762347966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.